MicroRNA profiling of laser-microdissected hepatocellular carcinoma reveals an oncogenic phenotype of the tumor capsule

Translational Oncology

Volumn 7, Issue 6, 2014, Pages 672-680

  Peveling Oberhag, Jan ^a   Seiz, Anna ^a   Döring, Claudia ^a   Hartmann, Sylvia ^a   Köberle, Verena ^a   Liese, Juliane ^a   Zeuzem, Stefan ^a   Hansmann, Martin Leo ^a   Piiper, Albrecht ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 100; MICRORNA 125A; MICRORNA 125B; MICRORNA 126; MICRORNA 146A; MICRORNA 199A; MICRORNA 214; MICRORNA 26A; MICRORNA 99A; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BIOINFORMATICS; CANCER GRADING; CANCER STAGING; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CONNECTIVE TISSUE TUMOR; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DOWN REGULATION; FEMALE; FIBROUS CAPSULE TUMOR; GENE EXPRESSION; HEPATITIS C; HISTOLOGY; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; LASER MICRODISSECTION; LASER PRESSURE CATAPULTING; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER PARENCHYMA; MALE; MOLECULAR PATHOLOGY; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRINCIPAL COMPONENT ANALYSIS; PROTEIN MICROARRAY; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84915792710     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2014.09.003     Document Type: Article

References (48)

1. Cabibbo G, Enea M, Attanasio M, Bruix J, Craxì A, and Cammà C (2010). A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 51, 1274–1283.
2. El Serag HB and Rudolph KL (2007). Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132, 2557–2576.
3. Llovet JM, Burroughs A, and Bruix J (2003). Hepatocellular carcinoma. Lancet 362, 1907–1917.
4. Jemal A, Bray F, Center MM, Ferlay J, Ward E, and Forman D (2011). Global cancer statistics. CA Cancer J Clin 61, 69–90.
5. El Serag HB and Mason AC (1999). Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340, 745–750.
6. Taura N, Yatsuhashi H, and Hamasaki K, et al (2006). Increasing hepatitis C virus-associated hepatocellular carcinoma mortality and aging: long term trends in Japan. Hepatol Res 34, 130–134.
7. Ekstedt M, Franzen LE, and Mathiesen UL, et al (2006). Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44, 865–873.
8. Ambros V (2004). The functions of animal microRNAs. Nature 431, 350–355.
9. Esquela-Kerscher A and Slack FJ (2006). Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer 6, 259–269.
10. Coulouarn C, Factor VM, Andersen JB, Durkin ME, and Thorgeirsson SS (2009). Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 28, 3526–3536.
11. Ji J, Zhao L, and Budhu A, et al (2010). Let-7g targets collagen type I α2 and inhibits cell migration in hepatocellular carcinoma. J Hepatol 52, 690–697.
12. Xiong Y, Fang JH, and Yun JP, et al (2010). Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 51, 836–845.
13. Borel F, Konstantinova P, and Jansen PL (2012). Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol 56, 1371–1383.
14. Toffanin S, Hoshida Y, and Lachenmayer A, et al (2011). MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology 140, 1618–1628.
15. Wong CM, Wong CC, Lee JM, Fan DN, Au SL, and Ng IO (2012). Sequential alterations of microRNA expression in hepatocellular carcinoma development and venous metastasis. Hepatology 55, 1453–1461.
16. Ladeiro Y, Couchy G, and Balabaud C, et al (2008). MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 47, 1955–1963.
17. Varnholt H, Drebber U, and Schulze F, et al (2008). MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology 47, 1223–1232.
18. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, and Patel T (2007). MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133, 647–658.
19. Su H, Yang JR, and Xu T, et al (2009). MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res 69, 1135–1142.
20. Wang Y, Lee AT, and Ma JZ, et al (2008). Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem 283, 13205–13215.
21. Llovet JM, Bru C, and Bruix J (1999). Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19, 329–338.
22. Edgar R, Domrachev M, and Lash AE (2002). Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30, 207–210.
23. Tan LP, Wang M, and Robertus JL, et al (2009). miRNA profiling of B-cell subsets: specific miRNA profile for germinal center B cells with variation between centroblasts and centrocytes. Lab Invest 89, 708–716.
24. Benjamini Y and Hochberg Y (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 57, 289–300.
25. Vlachos IS, Kostoulas N, and Vergoulis T, et al (2012). DIANA miRPath v. 2.0: investigating the combinatorial effect of microRNAs in pathways. Nucleic Acids Res 40, W498–W504.
26. Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, and Kanehisa M (1999). KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res 27, 29–34.
27. Peveling-Oberhag J, Doring C, and Hartmann S, et al (2015). Feasibility of global microRNA analysis from fine-needle biopsy FFPE material in patients with hepatocellular carcinoma treated with sorafenib. Clin Sci(Lond) 128, 29–37. http://dx.doi.org/10.1042/CS20140007.
28. Cheng AL, Kang YK, and Chen Z, et al (2009). Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10, 25–34.
29. Llovet JM, Ricci S, and Mazzaferro V, et al (2008). Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359, 378–390.
30. Murakami Y, Yasuda T, and Saigo K, et al (2005). Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 25, 2537–2545.
31. Sato F, Hatano E, and Kitamura K, et al (2011). MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan Criteria. PLoS One 6, e16435.
32. Kota J, Chivukula RR, and O'Donnell KA, et al (2009). Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancermodel. Cell 137, 1005–1017.
33. Chen G, Umelo IA, and Lv S, et al (2013).miR-146a inhibits cell growth, cellmigration and induces apoptosis in non-small cell lung cancer cells. PLoS One 8, e60317.
34. Felli N, Felicetti F, and Lustri AM, et al (2013). miR-126&126* restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma. PLoS One 8, e56824.
35. Jusufovic E, Rijavec M, and Keser D, et al (2012). let-7b and miR-126 are downregulated in tumor tissue and correlate with microvessel density and survival outcomes in non–small-cell lung cancer. PLoS One 7, e45577.
36. Sun D, Lee YS, and Malhotra A, et al (2011). miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation. Cancer Res 71, 1313–1324.
37. Zhang J, Han C, and Wu T (2012). MicroRNA-26a promotes cholangiocarcinoma growth by activating β-catenin. Gastroenterology 143, 246–256.e8.
38. Chen H, Miao R, and Fan J, et al (2013). Decreased expression of miR-126 correlates with metastatic recurrence of hepatocellular carcinoma. Clin Exp Metastasis 30, 651–658.
39. Gong J, Zhang JP, and Li B, et al (2013). MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R. Oncogene 32, 3071–3079.
40. Li D, Liu X, and Lin L, et al (2011). MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem 286, 36677–36685.
41. Petrelli A, Perra A, and Schernhuber K, et al (2012). Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression. Oncogene 31, 4517–4526.
42. Zhu Y, Lu Y, and Zhang Q, et al (2012). MicroRNA-26a/b and their host genes cooperate to inhibit the G1/S transition by activating the pRb protein. Nucleic Acids Res 40, 4615–4625.
43. Hernandez-Gea V, Toffanin S, Friedman SL, and Llovet JM (2013). Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 144, 512–527.
44. Utsunomiya YT, Pérez O'Brien AM, and Sonstegard TS, et al (2013). Detecting loci under recent positive selection in dairy and beef cattle by combining different genome-wide scan methods. PLoS One 8, e64280.
45. Chauhan VP, Martin JD, and Liu H, et al (2013). Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun 4, 2516.
46. Olive KP, Jacobetz MA, and Davidson CJ, et al (2009). Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457–1461.
47. El-Serag HB (2011). Hepatocellular carcinoma. N Engl J Med 365, 1118–1127.
48. Kanehisa M, Goto S, Kawashima S, Okuno Y, and Hattori M (2004). The KEGG resource for deciphering the genome. Nucleic Acids Res 32, D277–D280.